With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

The complement system has more than 50 soluble and membrane-bound proteins. In innate and adaptive immunity, complement is essential for eliminating foreign pathogens and apoptotic cells. It is also ...

In the last five years, neuronal pentraxins have emerged as potential markers of synaptic loss. In the case of NPTX2, researchers may now be able to explain why. In the March 29 Science Translational ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Undertaking a study of proteins found in the complement system, an important part of the immune system, of patients with long COVID, researchers have identified a blood protein ‘signature’ that may ...

In a recent study posted to the bioRxiv* preprint server, researchers investigated the expression of complement regulatory proteins (CRPs) in coronavirus disease 2019 (COVID-19) to identify potential ...

A panel of 48 proteins in the cerebrospinal fluid (CSF 48 panel) complements existing CSF biomarkers for Alzheimer disease (AD), according to a study published in the Sept. 6 issue of Science ...

Long COVID was identified in blood proteins, an analysis of longitudinal data suggested. Blood samples from long COVID patients showed changes to blood serum proteins at 6 months that indicated ...